Pharmaceuticals company Windlas Biotech announced Q3FY26 results Revenue from operations stood at Rs 233.1 crore as against Rs 195.0 crore, a growth of 20% YoY. EBITDA stood at Rs 24.4 crore as against Rs 24.6 crore, with a marginal 1% YoY variation. EBITDA Margin came in at 10.5%. PAT stood at Rs 14.9 crore as against Rs 15.6 crore, declined by 4% YoY. PAT Margin came in at 6.4%. Hitesh Windlass, Managing Director, Windlas Biotech, said: “India’s healthcare budget has crossed Rs 1 lakh crore, signaling stronger support for health infrastructure and affordable treatments. Chronic and sub-chronic therapeutic segments are expanding rapidly due to lifestyle shifts, dietary changes, and rising medicine consumption. Our expertise in fixed-dose combinations and modified-release formulations positions us well to cater to this growing demand and support India’s evolving healthcare needs. The Indian Pharmaceutical Market (IPM) grew 11.8% YoY in Q3FY26, with volume growth of 1.6%. Against this backdrop of modest industry volume growth, Windlas Biotech delivered another strong and consistent quarter, achieving record revenues with YoY growth of 19% in 9MFY26 and 20% in Q3FY26. We remained focused on creating value for our stakeholders. For the first nine months of FY26, the Company reported an earnings per share of Rs 24.02, reflecting a 12% YoY increase. We continue to invest in strengthening our manufacturing infrastructure. Our Injectables and Plant-2 Extn. facilities are paying off with rising contributions to overall growth, and Plant-6 is progressing towards mechanical completion by end of FY26. Looking ahead, we remain focused on creating long-term shareholder value through disciplined execution, diversification of our client base, operational efficiencies, talent development, and expansion across dosage forms.” Komal Gupta, CEO & CFO, Windlas Biotech, said: “Our Highest ever quarterly revenue streak holds steady for 12th quarter. Company reported YoY revenue growth of 19% in 9MFY26 and 20% in Q3FY26, with revenues from operations of Rs 666 crore and Rs 233 crore, respectively. This reflects our disciplined execution and robust performance aligned with stringent quality and regulatory norms. The Budget reaffirms healthcare and pharmaceuticals as strategic national priorities and the company is strategically positioned with our focus on quality manufacturing and scale to leverage estimated sectoral growth opportunities. Generic Formulations CDMO vertical grew 20% in 9MFY26 and 23% in Q3FY26, driven by expanding customer base, increasing wallet share and new product launches. Trade Generics & Institutional vertical grew 18% in 9MFY26 and 7% in Q3FY26. We remain focused on delivering Accessible, Affordable and Authentic medicines across our target geography of tier2 and tier-3 towns in India while also leveraging increased footprint of institutional purchase programs like Jan Aushadhi. Exports vertical grew 29% in 9MFY26 and 36% in Q3FY26 with increased penetration to RoW and semi-regulated markets. Excluding the impact of ESOP expenses, EBITDA for 9MFY26 was Rs 89 crore (13.3%) and PAT Rs 60 crore (9.0%), while Q3FY26 EBITDA stood at Rs 32 crore (13.6%) and PAT Rs 22 crore (9.6%). For 9MFY26 company reported EBITDA of Rs 79 crore and PAT of Rs 50 crore. For Q3FY26 Reported EBITDA was Rs 24 crore and PAT was Rs 15 crore. Our focus is on creating sustainable value for all stakeholders by delivering affordable, highquality medicines. We are committed to strengthening organizational capabilities that align manufacturing infrastructure, product strategy, and high-performing teams. We will continue to deepen customer partnerships, expand our product portfolio, de-risk the business, and reinforce operational and financial discipline.” Result PDF